These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23161636)

  • 1. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
    Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
    Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
    Sayahi H; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4804-7. PubMed ID: 21775138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
    Ngo SC; Zimhony O; Chung WJ; Sayahi H; Jacobs WR; Welch JT
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2430-5. PubMed ID: 17485499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
    Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
    Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
    Baughn AD; Deng J; Vilchèze C; Riestra A; Welch JT; Jacobs WR; Zimhony O
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5323-8. PubMed ID: 20876380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
    Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
    Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
    Rajendran V; Sethumadhavan R
    J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
    Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
    Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
    ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
    Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
    J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazinamide triggers degradation of its target aspartate decarboxylase.
    Gopal P; Sarathy JP; Yee M; Ragunathan P; Shin J; Bhushan S; Zhu J; Akopian T; Kandror O; Lim TK; Gengenbacher M; Lin Q; Rubin EJ; Grüber G; Dick T
    Nat Commun; 2020 Apr; 11(1):1661. PubMed ID: 32245967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
    Aragón LM; Garrigó M; Moreno C; Español M; Coll P
    J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
    Miyagi C; Yamane N; Yogesh B; Ano H; Takashima T
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):111-6. PubMed ID: 14972380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
    Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey].
    Ozkütük N; Ecemiş T; Sürücüoğlu S
    Mikrobiyol Bul; 2008 Oct; 42(4):585-90. PubMed ID: 19149079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
    Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
    Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.
    Boshoff HI; Mizrahi V; Barry CE
    J Bacteriol; 2002 Apr; 184(8):2167-72. PubMed ID: 11914348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.